By otakuyassine3@gmail.com 
Tokio Marine Asset Management Co. Ltd. increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,816 shares of the medical research company’s stock after acquiring an additional 676 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $1,393,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Algert Global LLC grew its position in Edwards Lifesciences by 38.4% in the 2nd quarter. Algert Global LLC now owns 4,616 shares of the medical research company’s stock valued at $426,000 after buying an additional 1,280 shares in the last quarter. Centaurus Financial Inc. grew its position in Edwards Lifesciences by 13.2% in the 2nd quarter. Centaurus Financial Inc. now owns 1,822 shares of the medical research company’s stock valued at $168,000 after buying an additional 212 shares in the last quarter. Czech National Bank grew its position in Edwards Lifesciences by 6.9% in the 3rd quarter. Czech National Bank now owns 122,715 shares of the medical research company’s stock valued at $8,098,000 after buying an additional 7,883 shares in the last quarter. GAMMA Investing LLC grew its position in Edwards Lifesciences by 21.6% in the 3rd quarter. GAMMA Investing LLC now owns 4,105 shares of the medical research company’s stock valued at $271,000 after buying an additional 730 shares in the last quarter. Finally, Alpha Financial Partners LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $693,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Insider Buying and Selling at Edwards Lifesciences
In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,000 shares of company stock worth $547,430 over the last 90 days. Insiders own 1.27% of the company’s stock.
Edwards Lifesciences Trading Down 1.4 %
Shares of EW stock opened at $71.46 on Tuesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $72.49 and its two-hundred day moving average is $69.73. The company has a market cap of $42.15 billion, a PE ratio of 10.31, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11.
Analyst Ratings Changes
Several equities analysts have recently weighed in on EW shares. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective for the company. in a research report on Thursday, January 16th. Piper Sandler reduced their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Citigroup raised their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $79.19.
Check Out Our Latest Research Report on Edwards Lifesciences
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Recommended Stories
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edwards Lifesciences and related companies with MarketBeat.com’s FREE daily email newsletter.